Gastrointestinal Tract Articles & Analysis
67 news found
Gastrointestinal (GI) and liver diseases are complex conditions that can greatly impact a person's quality of life. ...
They can be used for the delivery of small molecule drugs, biologics, vaccines, and even nucleic acids. By bypassing the gastrointestinal tract and avoiding first-pass metabolism, microneedle-based drug delivery allows for higher bioavailability and improved therapeutic outcomes. ...
These thin films are designed to dissolve rapidly in the mouth, delivering drugs directly into the bloodstream, bypassing the gastrointestinal tract. This technology not only offers convenience and ease of administration but also enhances drug bioavailability, making it an attractive option for patients. ...
Gut flora refers to the microorganisms living in the human intestinal tract, such as Bifidobacteria, Lactobacilli, etc. Over 10 trillion parasitic bacteria are present within the human intestinal tract. ...
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of ...
Suono Bio, a preclinical stage company, has developed breakthrough technology − the “SuonoCalmTM” system − designed to potentially enable ultra-rapid delivery of therapeutics across tissues, including the gastrointestinal (GI) tract. Preclinical studies have demonstrated that the ultrasound-based technology can deliver small molecules, ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
Just to name a few: first, the solubility of APIs in the dosage form will be improved; second, the dissolved state of the API in the gastrointestinal tract can be maintained for a longer time; third, increased bioavailability excipients can even co-work with the digestion and absorption of physiological lipids in the body to promote the absorption of drugs. ...
GEP-NETs are rare types of tumors originating in the pancreas or other parts of the gastrointestinal tract. Due to their heterogeneity and unique characteristics, early diagnosis is difficult, increasing the likelihood of metastatic disease and severely limiting treatment options. ...
Phages are the most common and widely distributed viruses and are usually found in abundance in areas filled with bacterial communities, such as soil and the gastrointestinal tract. Phages are not to be neglected for study when studying microecology. ...
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
Scintigraphic imaging visualized transit of the tablets through the gastrointestinal tract to confirm both the site and onset of release, which will then be correlated with pharmacokinetic data to establish the full release profile of the CTx-2103 formulation. ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program. Inversago scientists identified Diabetic Kidney Disease as the most ...
– Company to Webcast Investor Event on September 30th at 8:00 p.m. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment ...
No identifiable prior medical treatment; Impossibility for the patient to participate in prolonged medical follow-up; Unstable psychotic disorders, severe depressive syndromes that have not been stabilized with a specific treatment, suicidal tendencies; Alcoholism or drug addiction; Severe eating disorders (such as bulimia); An insufficient mastication coefficient; Documented ...
It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thus earning it an orphan-disease status. ...
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. ...
EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform. ...
C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. It requires no bowel preparation, allowing the patients to continue ...
EsoCap’s technology consists of a capsule containing a thin mucoadhesive film loaded with an active pharmaceutical ingredient (API) allowing the specific, site-directed treatment of diseases of the upper gastrointestinal tract. The first product candidate, ESO-101, is loaded with mometasone furoate. ...